Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718871 | 0.88 | MAPT (0.63) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL28038246 | 0.86 | ALDH1A1 (0.69) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL3538126 | 0.84 | ALDH1A1 (0.68) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL22094803 | 0.84 | ALDH1A1 (0.68) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL27646270 | 0.83 | MAPT (0.53) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL5322795 | 0.82 | ALDH1A1 (0.64) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL30953903 | 0.82 | MAPT (0.64) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL7809569 | 0.82 | MAPT (0.64) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL30699269 | 0.82 | MAPT (0.64) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 | |
| SCHEMBL20166477 | 0.82 | MAPT (0.64) | MAPTALDH1A1NPSR1SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230391734-A1 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF | NEUROPORE THERAPIES, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| CN-111372579-B | Substituted phenylsulfonyl phenyltriazolethiones and use thereof | 神经孔疗法股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11708338-B2 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof | NEUROPORE THERAPIES, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210300881-A1 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF | NEUROPORE THERAPIES, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | NEUROPORE THERAPIES, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-11008294-B2 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof | NEUROPORE THERAPIES, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3810133-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | Neuropore Therapies, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-112512523-A | Methods of treating conditions associated with neurodegenerative disorders using inhibitors of OAT3 | 神经孔疗法股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3703675-A1 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF | Neuropore Therapies, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111372579-A | Substituted phenylsulfonylphenyltriazolethiones and uses thereof | 神经孔疗法股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| US-6965036-B2 | Intermediates for guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2005-11-15 | — | — | US | disclosed |
| US-6958356-B2 | Guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| EP-0991638-B1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6906070-B2 | Anticoagulants | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040063772-A1 | Novel intermediates for guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-01 | — | — | US | disclosed |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-10 | — | — | US | disclosed |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-28 | — | — | US | disclosed |
| US-6339099-B1 | FOR THERAPY AND PROPHYLAXIS OF THROMBOEMBOLIC DISORDER | DUPONT PHARMACEUTICALS COMPANY | 2002-01-15 | — | — | US | disclosed |
| EP-0991638-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998057951-A1 | NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300881-A1 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF | TPMT, ABCB1, DPP8 | MAPT 2005/4885ALDH1A1 1945/4885NPSR1 1325/4885 |
| US-11008294-B2 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof | TPMT, ABCB1, DPP8 | MAPT 2005/4885ALDH1A1 1945/4885NPSR1 1325/4885 |
| US-20210290597-A1 | METHOD OF TREATING A CONDITION ASSOCIATED WITH NEURODEGENERATION USING INHIBITORS OF OAT3 | OAT, CLN6, SLC2A3 | MAPT 28/4885ALDH1A1 1925/4885NPSR1 994/4885 |
| US-20030069258-A1 | Novel guanidine mimics factor Xa inhibitors | TFPI, F11, F12 | MAPT 4607/4885ALDH1A1 2218/4885NPSR1 1475/4885 |
| US-20040063772-A1 | Novel intermediates for guanidine mimics as factor Xa inhibitors | TFPI, SERPINC1, F11 | MAPT 4561/4885ALDH1A1 1666/4885NPSR1 1512/4885 |
| US-11708338-B2 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof | TPMT, ABCB1, DPP8 | MAPT 2005/4885ALDH1A1 1945/4885NPSR1 1325/4885 |
| US-20230391734-A1 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF | TPMT, ABCB1, DPP8 | MAPT 2005/4885ALDH1A1 1945/4885NPSR1 1325/4885 |
| US-20020025963-A1 | Novel guanidine mimics as factor Xa inhibitors | F11, SERPINC1, TFPI | MAPT 4566/4885ALDH1A1 1803/4885NPSR1 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.